PDT Partners’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

PDT Partners’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-9,292	Closed	-$208K	–	493
2019 Q1	$208K	Sell	9,292 -15,193	-62%	-$327K	0.01%	392
2018 Q4	$446K	Sell	24,485 -15	-0.1%	-$235	0.02%	333
2018 Q3	$443K	Buy	24,500 +8,066	+49%	+$95.6K	0.02%	370
2018 Q2	$164K	Sell	16,434 -50,638	-75%	-$350K	0.01%	484
2018 Q1	$356K	Buy	67,072 +20,772	+45%	+$148K	0.01%	479
2017 Q4	$394K	Buy	+46,300	New	+$569K	0.01%	460

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

PDT Partners's RARX Position: Q2 2019 in Review

PDT Partners sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2019, closing a stake of 9,292 shares — an estimated $208K sold.

PDT Partners first reported a position in RARX in Q4 2017 and held it in 6 quarters. The position peaked at $446K in Q4 2018. 118 funds tracked by Wall St. Rank hold RARX as of Q2 2019.

PDT Partners reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
PDT Partners sold 9,292 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2019, an estimated $208K.
PDT Partners first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 6 quarters.
PDT Partners's Ra Pharmaceuticals, Inc. Common Stock position peaked at $446K in Q4 2018.
118 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2019.

Based on PDT Partners's 13F filing for Q2 2019, filed 14 Aug 2019.